[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dyslipidaemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dyslipidaemia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,83,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100629404","associations-between-dietary-patterns-ldl-aggregation-and-cardiometabolic-health-a-cross-sectional-analysis-100629404",false,"NCT07474233","Associations Between Dietary Patterns, LDL Aggregation, and Cardiometabolic Health: A Cross-sectional Analysis.","Associations Between Dietary Pattern Adherence, LDL Aggregation, and Cardiometabolic Health: A Cross-sectional Analysis.","Inclusion Criteria:\n\n* Adults aged 25-60 years.\n* BMI range (18.5-29.9 kg\u002Fm²).\n* Following one of the specified dietary patterns (vegan\u002Fplant-based, carnivore, or omnivorous) for a minimum of 6 months.\n* Self-identified as health-focused (i.e., intentionally following the diet for perceived health benefits).\n\nExclusion Criteria:\n\n* BMI outside the stated range (\\\u003C18.5 or ≥30 kg\u002Fm²).\n* Use of lipid-lowering medications or supplements that may interfere with LDL levels.\n* Pregnancy or breastfeeding.\n* Any significant deviation from the specified diet within the last month.",true,"ALL","25 Years","60 Years",{"count":21,"type":22},90,"ESTIMATED","OBSERVATIONAL","This study aims to investigate the extent to which vegan or plant-based, omnivorous, and carnivore dietary patterns affect LDL aggregation susceptibility (the affinity for LDL cholesterol particles to clump together in the blood), which may promote plaque build-up in arteries. Using a cross-sectional mixed-methods design, the study will measure LDL aggregation, blood lipids, and other metabolic biomarkers in individuals following these diets, and combine these data with dietary and behavioural information to examine links with cardiovascular and metabolic health.",[26,27,28,29],"Atherosclerosis Cardiovascular Disease","Metabolic Syndrome","Dyslipidaemia","Endothelial Dysfunction",[31,32,33,34,35,36,37,38,39],"LDL aggregation","Dietary patterns","Atherosclerosis","Cardiovascular disease","Onmivore diet","Vegan diet","Carnivore diet","Lipid profile","Cardiometabolic health","NOT_YET_RECRUITING","2026-03-11",{"date":43,"type":44},"2026-03-16","ACTUAL",{"date":46,"type":22},"2026-05",{"date":48,"type":22},"2027-05",{"name":50,"class":51},"Liverpool John Moores University","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":16,"sex":17,"minAge":61,"maxAge":19,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":69,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":52},"100628533","comparative-effects-of-carnivore-and-mediterranean-style-diets-on-ldl-aggregation-and-cardiometabolic-health-100628533","NCT07462871","Comparative Effects of Carnivore and Mediterranean-style Diets on LDL Aggregation and Cardiometabolic Health","Comparative Effects of Carnivore and Mediterranean-style Diets on LDL Aggregation Susceptibility and Cardiometabolic Health","MEDIVORE","Inclusion Criteria:\n\n* Male or female\n* 30-60 years of age\n* Elevated LDL cholesterol (LDL \\>3mmol\u002FL and\u002For non-HDL cholesterol \\> 4mmol\u002FL)\n* Not following any specific diet for health reasons.\n* Not currently taking lipid-lowering medications or supplements that may interfere with LDL levels.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Known food allergies or intolerances.\n* Previous history of disordered eating.\n* Currently taking cholesterol-lowering medication or supplements.","30 Years",{"count":63,"type":22},30,"INTERVENTIONAL",[66],"NA","The goal of this clinical trial is to learn whether following a Mediterranean-style diet or a Carnivore-style diet can improve heart and metabolic health in men and women aged 30-60 years with high LDL cholesterol.\n\nThe main questions it aims to answer are:\n\n1. Does following a Mediterranean or Carnivore diet change how easily LDL cholesterol particles clump together (LDL aggregation susceptibility)?\n2. Do these two diets have different effects on other measures of heart and metabolic health, such as blood fats, blood vessel function, and overall wellbeing?\n\nResearchers will compare people who follow the Mediterranean-style diet with those who follow the Carnivore-style diet to see which diet produces more beneficial changes in cholesterol and heart health markers.\n\nParticipants will:\n\n* Attend three visits at Liverpool John Moores University for screening and data collection.\n* Be randomly assigned to follow either the Mediterranean or Carnivore diet for 3 weeks, matched for calories and protein.\n* Provide fasting blood, urine, and stool samples before and after the diet period.\n* Complete non-invasive cardiovascular tests to measure blood vessel and heart function.\n* Take part in a short interview and complete questionnaires about their experience of following the diet.",[26,27,28],[33,70,71,72,31,73,74,75],"ASCVD","Diet, carbohydrate-restricted","Ketogenic diet","Low-density lipoproteins","Lipoproteins","Lipid metabolism",{"date":77,"type":44},"2026-03-13",{"date":79,"type":22},"2026-06",{"date":81,"type":22},"2027-06",{"name":50,"class":51},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":64,"phases":95,"briefSummary":96,"conditions":97,"keywords":102,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":52},"100584502","onestop-one-stop-telehealth-obesity-program-for-multidisciplinary-weight-management-and-related-comorbidities-100584502","NCT06890169","OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities","OneSTOP (One-Stop Telehealth Obesity Program): the Use of Telecare and Digital Platforms for Multidisciplinary Management of Weight Management and Related Comorbidities","OneSTOP","Inclusion Criteria:\n\n* Adults aged 21-70\n* Body mass index \\> 27.5 kg\u002Fm2\n* Waist circumference \\> 90 cm in men or 80 cm in women\n* Suboptimal control of type 2 diabetes (HbA1c \\> 6.5%) AND\u002FOR MASLD (as defined on radiological or histological evidence of hepatic steatosis in the absence of other chronic liver disease)\n\nExclusion Criteria:\n\n* Men who drink \\> 21 units\u002Fweek and women who drink \\> 14 units\u002Fweek of alcohol\n* Participants previously on weight-lowering medications (however if they are keen to participate, there will be a minimum wash-out period of 3 months before participation)\n* Illness with life expectancy of less than 6 months\n* Inability to comply with written instructions in English","21 Years","70 Years",{"count":94,"type":22},120,[66],"The goal of this clinical trial is to learn if the use of a care model including teleconsults and the EMPOWER app can induce clinically significant weight loss and metabolic improvements in obese adults with diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD).\n\nResearchers will compare this model with the conventional standard of care of physical visit-based weight management program to see if this model is non-inferior to the standard of care for inducing weight loss, and if there is greater patient convenience with telehealth and more frequent self-monitoring, compliance with diet advice and exercise participation compared to standard of care.\n\nParticipants in the standard arm will attend 4 physical doctor and 4 physical dietician consultations over 26 weeks, where they will be provided with an individualized diet and exercise prescription to induce at least 5% weight loss.\n\nParticipants in the intervention arm will have the same number of consults over 26 weeks, of which at least 50% will be teleconsults, and will also be provided with an individualized diet and exercise prescription to induce at least 5% weight loss. In addition, they will be taught to use the EMPOWER app to upload weight, blood pressure and glucose, food and exercise records which will be reviewed at the consults. The app also delivers nudges to improve adherence to lifestyle modification.",[98,99,100,28,101],"Obesity and Type 2 Diabetes","NAFLD - Non-Alcoholic Fatty Liver Disease","Hypertension","Telemedicine",[103,104,105,106,107,108],"obesity","type 2 diabetes","masld","nafld","telecare","telemedicine","RECRUITING","2025-03-17",{"date":112,"type":44},"2025-03-21",{"date":114,"type":22},"2025-05-01",{"date":116,"type":22},"2027-08-31",{"name":118,"class":51},"Changi General Hospital",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":129,"studyType":23,"phases":4,"briefSummary":130,"conditions":131,"keywords":142,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100396456","the-european-nafld-registry-100396456","NCT04442334","The European NAFLD Registry","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Clinically suspected NAFLD based on any of:\n\n   1. Patient with historical liver biopsy providing histological evidence of NAFLD or,\n   2. Patient undergoing liver biopsy for suspected NAFLD with biochemical and\u002For radiological findings consistent with NAFLD or,\n   3. Patient with radiological evidence of cirrhosis (in absence of an alternative aetiology) plus presence of ≥2 features indicative of the 'metabolic syndrome':\n\n      * Increased waist circumference by ethnically adjusted criteria (e.g. Europid male\u002Ffemale ≥94cm\u002F80cm) or overweight\u002Fobese (BMI ≥25);\n      * Raised fasting glucose ≥100 mg\u002FdL \\[5.6 mmol\u002FL\\], HbA1c ≥48mmol\u002Fmol (6.5%) or previously diagnosed insulin resistance\u002Ftype 2 diabetes mellitus (or on treatment);\n      * Dyslipidaemia (fasting TG level ≥150 mg\u002FdL \\[1.7 mmol\u002FL\\]; or fasting HDL \\\u003C40 mg\u002FdL \\[1.03 mmol\u002FL\\] in males and \\\u003C50 mg\u002FdL \\[1.29 mmol\u002FL\\] in females; or on treatment);\n      * Hypertension (systolic BP ≥130 or diastolic BP ≥85 mmHg, or on treatment).\n3. Average alcohol consumption less than 21\u002F14 units\u002Fweek (males\u002Ffemales) in preceding 6 months and no history of sustained excessive consumption of alcohol in past 5 years.\n\nExclusion Criteria\n\n1. Refusal or inability (lack of capacity) to give informed consent.\n2. Average alcohol ingestion greater than approximately 21\u002F14 units\u002Fweek (males\u002Ffemales) in preceding 6 months or history of sustained excessive consumption of alcohol in past 5 years.\n3. History or presence of Type 1 diabetes mellitus.\n4. Presence of any other form of chronic liver disease except NAFLD.\n5. Recent (within 12 months) or concomitant use of agents known to cause hepatic steatosis (long-term systemic corticosteroids \\[\\>10 days\\], amiodarone, methotrexate, tamoxifen, tetracycline, high dose oestrogens, valproic acid).\n6. Any contra-indication to liver biopsy.\n7. Recent (within 3 months) change in dose\u002Fregimen or introduction of Vitamin E (at a dose ≥400 IU\u002Fday), betaine, s-adenosyl methionine, ursodeoxycholic acid, silymarin or pentoxifylline.\n8. Non-English speaking\u002Funable to access an interpreter. Due to the nature of the study, English language or access to a relevant interpreter is a necessary criterion to ensure lifestyle (diet and exercise) and symptom data are collated.\n9. Patients not meeting inclusion criteria or judged by the investigator to be unsuitable for inclusion in the study.","18 Years","100 Years",{"count":128,"type":22},10000,"10 Years","The European NAFLD Registry is a prospectively recruited, observational study supporting the study of the clinical phenotype, natural history, disease outcomes and pathophysiology of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. The ultimate goals are to better understand the drivers of interpatient variation in disease pathophysiology and severity and to utilise this information to develop and validate biomarkers that, singly or in combination, enable detection and monitoring of disease progression and\u002For from NAFL through NASH to fibrosis and cirrhosis.",[132,133,134,135,136,137,138,139,28,100,140,141],"NAFLD","NASH","NASH - Nonalcoholic Steatohepatitis","Fibrosis, Liver","Steatosis of Liver","Hepatocellular Carcinoma","Cardiovascular Diseases","Type 2 Diabetes","Obesity","Other Associated Comorbidities",[132,133,143,144,145,146],"Steatohepatitis","Liver","Cirrhosis","Non-alcoholic fatty liver disease","2023-01-05",{"date":149,"type":44},"2023-01-06",{"date":151,"type":44},"2015-05-01",{"date":153,"type":22},"2030-12-31",{"name":155,"class":51},"Newcastle University",37]